X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The first project will advance lead HTX-001, an antisense oligonucleotide targeting lncRNA Wisper, a cardiac tissue-enriched driver of fibrosis in the heart and second project will aim to develop a next-generation oncology therapy targeting cancer-associated fibroblast.
Lead Product(s): HTX-001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HTX-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innosuisse
Deal Size: $3.3 million Upfront Cash: Undisclosed
Deal Type: Funding May 03, 2022
Details:
HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics HTX-001, that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.
Lead Product(s): HTX-001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HTX-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Broadview Ventures
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
